Possible mechanisms of the formation of chronic fatigue syndrome in the clinical picture of multiple sclerosis.
Kasatkin, D S, Spirin, N N · Neuroscience and behavioral physiology · 2007 · DOI
Quick Summary
This study examined why people with multiple sclerosis (MS) often experience severe fatigue. The researchers identified different types of fatigue—exhaustion at rest, excessive tiredness after activity, and worsening fatigue during MS flare-ups—and explored how brain chemistry, hormones, immune system problems, and sleep issues might all contribute to this fatigue.
Why It Matters
Understanding the multiple biological pathways underlying different types of fatigue—particularly distinguishing rest fatigue from exertional fatigue—could help clinicians better diagnose and treat fatigue in both MS and ME/CFS, which share similar neurological and immunological features. The proposed common mechanisms (neurotransmitter dysfunction, autoimmune activation) may apply broadly to post-infectious and demyelinating conditions.
Observed Findings
Chronic fatigue in MS can be categorized into asthenia (fatigue at rest), pathological fatigability (fatigue with exertion), and symptom-exacerbation fatigue.
Fatigue frequently co-occurs with depression and sleep disorders in MS patients.
Both central and peripheral mechanisms contribute to fatigue formation in MS.
Autoimmune factors appear to have greater influence on asthenia than on pathological fatigability.
Decreased serotonergic and noradrenergic system activity may underlie both fatigue and associated mood/sleep disturbances.
Inferred Conclusions
Asthenia and pathological fatigability likely represent distinct biological phenomena requiring different diagnostic and therapeutic approaches.
Common neurochemical mechanisms (serotonin/norepinephrine dysregulation) may explain the clustering of fatigue, depression, and sleep disorders in MS.
Autoimmune and endocrine dysfunction contribute meaningfully to fatigue pathogenesis, with differential effects depending on fatigue phenotype.
Future research should differentiate between rest fatigue and exertional fatigue to improve treatment selection.
Remaining Questions
What specific biomarkers or immune factors most strongly predict asthenia versus pathological fatigability?
What This Study Does Not Prove
This review does not provide direct experimental evidence for its proposed mechanisms and relies on synthesis of prior literature rather than new data. It does not establish causation or prove that the identified mechanisms are primary drivers of fatigue versus secondary effects. The applicability to ME/CFS specifically (which is not a demyelinating disease) remains unclear.
How do serotonergic and noradrenergic system abnormalities mechanistically generate different fatigue phenotypes?
Can findings from MS fatigue mechanistic research be meaningfully translated to ME/CFS given the different underlying pathology (demyelination vs. suspected post-infectious)?
Which treatments specifically target asthenia versus exertional fatigue, and how should they be selected based on fatigue phenotype?